Searchable abstracts of presentations at key conferences in endocrinology

ea0063p211 | Diabetes, Obesity and Metabolism 1 | ECE2019

Pattern of C-peptide response to oral glucose tolerance test: interest and reference values

Bonnet-Serrano Fideline , Bouzerara Amina , Abou Jaoude Mathieu , Gobeaux Camille , Mosnier-Pudar Helen , Guibourdenche Jean

Introduction: Oral glucose tolerance test (OGTT) allows classification of subjects in 3 groups, depending on glycaemia 120 minutes after 75 g glucose ingestion: normal (glycaemia < 1.4 g/L), glucose intolerant (1.4–2 g/L) and diabetic (>2 g/L). Five insulin profiles associated with different incidence rates of diabetes over 10 years of follow-up have also previously been described. Insulin measurement is very sensible to hemolysis and can advantageously be replace...

ea0063p321 | Reproductive Endocrinology 1 | ECE2019

Automated free testosterone assay: validation and usual values

Bonnet-Serrano Fideline , Bouzerara Amina , Rousselle Theo , Menet Marie-Claude , Guibourdenche Jean

Introduction: Testosterone circulates under different forms in blood, mainly bound to proteins i.e. Sex Hormone Binding Globulin (SHBG) and albumin. Free testosterone (FT), the biologically active form, represents 2% of total testosterone (TT). FT measurement is mainly indicated when TT level is discordant with clinical picture but remains technically challenging. Indeed, as for all free hormones, gold standard method relies on equilibrium dialysis, unusable in routine. Direct...

ea0063p642 | Interdisciplinary Endocrinology 1 | ECE2019

To what extend biotin interferes with hormones immunoassays?

Bouzerara Amina , Pavard Juliette , Bonnet-Serrano Fideline , Jaoude Mathieu Abou , Guibourdenche Jean

Introduction: Biotin (vitamin B8) is a coenzyme of carboxylases involved in many metabolic pathways and also used in therapeutics as a dietary supplement (diffuse alopecia)(<30 mg/day), in the treatment of rare congenital enzymatic deficiencies (5–40 mg/day) or more recently in the treatment of progressive multiple sclerosis at higher doses (300 mg/day). At such high doses, interferences with thyroid hormones assays using biotin-streptavidin amplification system were ...

ea0037ep154 | Reproduction, endocrine disruptors and signalling | ECE2015

Analysis of gonadal steroid secretion in the serum of women during ovarian stimulation

Menet Marie Claude , Damiens Guillaume , Metenier Erwan , Sraouia Nacera , Leguy Marie Clemence , Gayet Vanessa , Guibourdenche Jean

Introduction: Biochemical follow up of the ovarian function after ovarian stimulation is restricted to the measurement of serum oestradiol and progesterone. We aim to investigate the entire ovarian steroidognesis after ovarian stimulation.Materials and methods: 50 women (26 IVF and 24 ICSI) who underwent AMP induction (based on rFSH stimulation after GnRH agonist or antagonist) for the same cause of infertility were retrospectively involved and compared ...

ea0056gp119 | Endocrine Case Reports | ECE2018

Non-syndromic multiple insulinomas with atypical clinico-biological presentation in two adult patients: a specific entity?

Bonnet-Serrano Fideline , Lethielleux Gaelle , Gaujoux Sebastien , North Marie-Odile , Terris Benoit , Guibourdenche Jean , Bertherat Jerome

Introduction: Insulinoma is the most frequent functional endocrine tumor of the pancreas but remains rare with an incidence of less than 5 cases by million and by year. It is often sporadic but can occur in the context of MEN1 in about 5% of cases, being then readily multiple. Clinically, it is typically responsible for fasting hypoglycemic episodes. Only one case of multiple insulinomas, with no obvious argument for MEN1 context, has previously been reported (Babic an al., <e...

ea0041gp202 | Thyroid - Translational &amp; Clinical | ECE2016

Does mitotane influence free thyroid hormones levels? A possible explanation in vivo and in vitro

Blanchet Benoit , Clemence Leguy Marie , Le Monnier Aude , Habbas Halim , Claude Menet Marie , Groussin Lionel , Guibourdenche Jean

Mitotane (o.p’DDD, Lysodren) is used to treat adrenortical carcinoma and Cushing syndromes. It is catabolised into o.p’DDA and o.p’DDE. It is lowly protein-bound but its tropism for lipids is high. It has multiple side effects on the digestive gut increasing alkaline phosphatases and cholesterol. Patients treated with mitotane have been described as having decreased FT4 levels without any signs of hypothyroidism. We wanted to know whether this is due to an analy...

ea0059p195 | Reproduction | SFEBES2018

Exhaustive characterization of placental production of progesterone in vitro

Fraichard Camille , Hebert-Schuster Marylise , Garnier Anthony , Sibiude Jeanne , Bouzerara Amina , Fournier Thierry , Trabado Severine , Guibourdenche Jean

Placenta is an endocrine organ, secreting steroids (progesterone [P4], estrogens) and hCG, thanks to villous tissu (cytotrophoblasts [VCT] and syncytiotrophoblast [ST]). P4 is required for implantation and maintenance of pregnancy. P4 is synthetized from maternal cholesterol thanks to mitochondrial transporter MLN64 and P450SCC and HSD3B1 enzymes. We aimed to characterize P4 production in human placenta during VCTs differentiation into ST in vitro. VCTs isolated from ...

ea0081oc7.4 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

HPLC-MSMS steroidogenic profiles in ACTH-dependent Cushing Syndrome patients treated by osilodrostat or metyrapone suggest differences in the spectrum of steroidogenic enzyme inhibition between the two CYP11B1 inhibitors in clinical care

Fideline Bonnet , Poirier Jonathan , Vaczlavik Anna , Laguillier-Morizot Christelle , Blanchet Benoit , Guignat Laurence , Bessiene Laura , Bricaire Leopoldine , Groussin Lionel , Assie Guillaume , Guibourdenche Jean , Bertherat Jerome

Introduction: Osilodrostat is a new 11 ß-hydroxylase inhibitor with a mode of action analogue to metyrapone. It has become increasingly used in recent years for treatment of Cushing’s Syndrome (CS). However, few in vivo studies are currently available to accurately compare both drugs characteristics. The objective of our study was to compare steroidogenic profiles in patients treated by either Osilodrostat or Metyrapone for ACTH-dependent CS.Me...

ea0090oc3.5 | Oral Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Interest of serum and salivary cortisol diurnal cycle in the positive diagnostic of Cushing syndrome and in the differential diagnosis of pseudo-Cushing syndrome

Fideline Bonnet , Poirier Jonathan , El Khoury Ralph , Laguillier-Morizot Christelle , Leguy Marie-Clemence , Thomeret Louis , Bouys Lucas , Guignat Laurence , Assie Guillaume , Groussin Lionel , Guibourdenche Jean , Bertherat Jerome

Introduction: Biological diagnosis of Cushing syndrome relies on three parameters: 24 hours-free urinary cortisol; serum cortisol after 1 mg dexamethasone suppression test; late-night serum or salivary cortisol. These tests allow the diagnosis of cortisol excess but do not help in etiological diagnosis, particularly in the distinction between pseudo-Cushing and ACTH-dependent Cushing syndrome, which is often challenging. The aim of this study was to evaluate the performances o...

ea0073oc9.5 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Reassessment of the diagnostic criteria of insulinoma: A retrospective monocentric cohort study of 72-h fasting trial in 124 patients

Fideline Bonnet , Devingenteuil Clara , Vaczlavik Anna , Bessiene Laura , Laguillier-Morizot Christelle , Assié Guillaume , Helen Mosnier-Pudar , Terris Benoît , Groussin Lionel , Guibourdenche Jean , Bertherat Jerome

IntroductionFasting trial remains the gold standard to confirm the diagnosis of insulinoma, based on low blood glucose level concomitant with inadequate high insulin level. However, diagnostic criteria are not consensual. Glycemia and insulin thresholds differ between the different consensus statements : endogenous hyperinsulism diagnosis relies on a glycemia < 3 mmol/l associated with an insulin level > 3 mUI/l in Endocrine Society guidelines (2009)...